期刊文献+

熊果酸半乳糖苷偶联物的合成及保肝活性 被引量:4

Synthesis and Hepatoprotective Activity of Glycoside Conjugates of Ursolic Acid
下载PDF
导出
摘要 通过改进的Koenigs-knorr法在熊果酸3位和28位进行半乳糖苷化得到6个化合物.通过MTT法考察了上述化合物对大鼠肝干细胞样上皮细胞WB-F344的作用,发现化合物12b和12e可明显提高WB-F344细胞的成活率.体内实验结果表明,化合物12b,12d和12f在刀豆蛋白引起的小鼠急性免疫性肝损伤模型上,除化合物12d对小鼠血清谷草转氨酶升高具有一定程度的降低作用外,其余化合物均未见对谷草和谷丙转氨酶的升高表现出明显的保护作用. Ursolic acid was reported that it could be used for liver protection. However, its usage is restricted by its poor solubility in water. To improve the hepatoprotective activity of ursolic acid, some novel derivatives of ursolic were designed and synthesized. By modified Koenigs-knorr method, six glycoside conjugates of ursolic acid with modification at C3 and/or C28 were synthesized. It was found that compounds 12b and 12e could obviously increase the survival rate of WB-F344 rat hepatic stem-like epithelial cells evaluated through MTT method at cellular level. In vivo, however, it was not found that compounds 12b, 12d and 12f could obviously prevent the rise of the level of serum transaminases induced by ConA in a mice acute immunity liver damage model except that compound 12d could reduce the level of aspartate aminotransferase(AST) to some extent. By the introduction of galactose moieties, the liver protection potency of ursolic acid was improved.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2013年第7期1660-1666,共7页 Chemical Journal of Chinese Universities
基金 北京市自然科学基金(批准号:7102114) 科技部创新药物专项(批准号:2009ZX09301-003-4-1,2009ZX09311-004)资助
关键词 熊果酸 半乳糖苷 保肝活性 Ursolic acid Glycoside conjugates Hepatoprotective activity
  • 相关文献

参考文献23

  • 1Chiang L. C.,Chiang W.,Chang M. Y.,Ng L. T. Lin C. C.,Am. J. Chin. Med. , 2003 , 3i(l), 37-46.
  • 2Sohn K. H.,Lee H. Y.,Chung H. Y.,Young H. S.,Yi S. Y.,Cancer Lett.,1995, 94(2),213-218.
  • 3张文娟,陈少鹏,陆鑫,周国春.熊果酸衍生物的合成及抗肿瘤血管生成活性[J].高等学校化学学报,2010,31(11):2206-2217. 被引量:7
  • 4Kashiwada Y.,Wang H. K.,Nagao T.,Kitanaka S.,Yasuda I.,Fujioka T.,Yamagishi T. , Cosentino L. M.,Kozuka M.,OkabeH.,Ikeshiro Y.,Hu C. Q. , Yeh E.,Lee K. H.,J. Nat. Prod.,1998, 61(9), 1090-1095.
  • 5Ismaili H.,Sosa S.,Brkic D. , Fkih-Tetouani S.,Ilidrissi A.,Touati D.,Aquino R. P.,Tubaro A.,J. Pharm. PharmacoL,2002,5^(8), 1137-1140.
  • 6Ismaili H. , Tortora S.,Sosa S.,Fkih-Tetouani S.,Iiidrissi A.,Della L. R.,Tubaro A.,Aquino R.,J. Pharm. PharmacoL,2001,55(12), 1645-1652.
  • 7Bariceivic D.,Sosa S.,Della L. R.,Tubaro A.,Simonovska B.,Krasna A.,Zupancic A.,J. Ethnopharmacol.,2001,75(2/3),125-132.
  • 8Shukla B.,Visen P. K. S.,Patnaik G. K.,Tripathi S. C.,Srimal R. C. , Dayal R.,Dobhal P. C.,Pkytotker. Res.,2006, 6(2),74-79.
  • 9Martin-Aragon S.,de las Heras B.,Sanchez-reus M. I.,Benedi J,,Exp. Toxicol. Pathol.,2001, 53 (2/3 ) , 199206.
  • 10熊筱娟,陈武,肖小华,徐丽英,崔江龙.乌索酸与齐墩果酸对小鼠实验性肝损伤保护作用的比较[J].江西师范大学学报(自然科学版),2004,28(6):540-543. 被引量:30

二级参考文献43

  • 1张乐之,李新芳.齐墩果酸对大鼠实验性肝损伤作用机理的研究[J].中药药理与临床,1992,8(2):24-26. 被引量:35
  • 2熊筱娟,陈武,肖小华,徐丽英,崔江龙.乌索酸与齐墩果酸对小鼠实验性肝损伤保护作用的比较[J].江西师范大学学报(自然科学版),2004,28(6):540-543. 被引量:30
  • 3张均田.现代药理学实验方法[M].北京医科大学中国协和医科大学联合出版社,1998.739.
  • 4Folkman J..New Engl.J.Med.[J] ,1971,285(21):1182-1186.
  • 5Liu J..J.Ethnopharmacol.[J] ,1995,49(2):57-68.
  • 6Sarawat B.,Visen P.K.S.,Dayal R.,Agarwal D.P.,Patnaik G.K..Indian J.Pharmacol.[J] ,1996,28(4):232-239.
  • 7Li J.,Guo W.J.,Yang Q.Y..World J.Gastroenterol.[J] ,2002,8(3):493-495.
  • 8Cha H.J.,Bae S.K.,Lee H.Y..Cancer Res.[J] ,1996,56(10):2281-2284.
  • 9Kiran M.S.,Viji R.I.,Sameer Kumar V.B.,Sudhakaran P.R..Biochem.Biophys.Res.Comm.[J] ,2008,371(3):556-560.
  • 10Armarego W.L.F.,Christina C..Purification of Laboratory Chemicals,Fifth Edition[M] ,Oxford:Butterworth-Heinemann,2003.

共引文献35

同被引文献25

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部